1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

New number of shares and votes in Senzime AB (publ)

LHFI

As previously announced, the board of directors of Senzime resolved on a directed issue of maximum 1,137,500 shares to the company’s chairman of the board Adam Dahlberg on August 24, 2023. The directed share issue was approved on the extraordinary general meeting on September 20, 2023.

The directed share issue has now been subscribed, paid for, and registered. The number of shares and votes in Senzime has therefore increased, and as of September 29, 2023, the total number of shares in Senzime amounts to 100,122,614 (previously 98,985,114 shares), with one vote each. The share capital amounts to SEK 12,515,326.75 (previously SEK 12,373,139.25).
As of September 29, 2023, Senzime holds no treasury shares.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
 
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-29 14:00 CEST.

Attachments

New number of shares and votes in Senzime AB (publ)

Datum 2023-09-29, kl 14:00
Källa MFN
Bifogade filer
New number of shares and votes in Senzime AB (publ)